141 related articles for article (PubMed ID: 35247898)
1. Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.
Osorio JC; Zamarin D
Cancer Res; 2022 Mar; 82(5):766-768. PubMed ID: 35247898
[TBL] [Abstract][Full Text] [Related]
2. IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer.
Mandal G; Biswas S; Anadon CM; Yu X; Gatenbee CD; Prabhakaran S; Payne KK; Chaurio RA; Martin A; Innamarato P; Moran C; Powers JJ; Harro CM; Mine JA; Sprenger KB; Rigolizzo KE; Wang X; Curiel TJ; Rodriguez PC; Anderson AR; Saglam O; Conejo-Garcia JR
Cancer Res; 2022 Mar; 82(5):859-871. PubMed ID: 34949671
[TBL] [Abstract][Full Text] [Related]
3. Potential role of tumor-infiltrating T-, B-lymphocytes, tumor-associated macrophages and IgA-secreting plasma cells in long-term survival in the rectal adenocarcinoma patients.
Zinovkin DA; Kose SY; Nadyrov EA; Achinovich SL; Los' DM; Gavrilenko TE; Gavrilenko DI; Yuzugulen J; Pranjol MZI
Life Sci; 2021 Dec; 286():120052. PubMed ID: 34656554
[TBL] [Abstract][Full Text] [Related]
4. IgA transcytosis and antigen recognition govern ovarian cancer immunity.
Biswas S; Mandal G; Payne KK; Anadon CM; Gatenbee CD; Chaurio RA; Costich TL; Moran C; Harro CM; Rigolizzo KE; Mine JA; Trillo-Tinoco J; Sasamoto N; Terry KL; Marchion D; Buras A; Wenham RM; Yu X; Townsend MK; Tworoger SS; Rodriguez PC; Anderson AR; Conejo-Garcia JR
Nature; 2021 Mar; 591(7850):464-470. PubMed ID: 33536615
[TBL] [Abstract][Full Text] [Related]
5. Pro- and Anti- Effects of Immunoglobulin A- Producing B Cell in Tumors and Its Triggers.
Zhong Z; Nan K; Weng M; Yue Y; Zhou W; Wang Z; Chu Y; Liu R; Miao C
Front Immunol; 2021; 12():765044. PubMed ID: 34868013
[TBL] [Abstract][Full Text] [Related]
6. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment: No Effector T Cells without Dendritic Cells.
Pfirschke C; Siwicki M; Liao HW; Pittet MJ
Cancer Cell; 2017 May; 31(5):614-615. PubMed ID: 28486102
[TBL] [Abstract][Full Text] [Related]
8. Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced
Garaud S; Zayakin P; Buisseret L; Rulle U; Silina K; de Wind A; Van den Eyden G; Larsimont D; Willard-Gallo K; Linē A
Front Immunol; 2018; 9():2660. PubMed ID: 30515157
[TBL] [Abstract][Full Text] [Related]
9. B cells, plasma cells and antibody repertoires in the tumour microenvironment.
Sharonov GV; Serebrovskaya EO; Yuzhakova DV; Britanova OV; Chudakov DM
Nat Rev Immunol; 2020 May; 20(5):294-307. PubMed ID: 31988391
[TBL] [Abstract][Full Text] [Related]
10. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
11. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
12. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.
Zheng M; Li YM; Liu ZY; Zhang X; Zhou Y; Jiang JL; Zhu P; Yang XM; Tang J; Chen ZN
Front Immunol; 2021; 12():731329. PubMed ID: 35069521
[TBL] [Abstract][Full Text] [Related]
14. IgA transcytosis: A new weapon in the immune response to cancer?
Laumont CM; Nelson BH
Cancer Cell; 2021 May; 39(5):607-609. PubMed ID: 33974859
[TBL] [Abstract][Full Text] [Related]
15. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
17. ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.
Sun L; Wang RC; Zhang Q; Guo LL
Pathol Res Pract; 2020 Aug; 216(8):153032. PubMed ID: 32703496
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment.
Ma F; Vayalil J; Lee G; Wang Y; Peng G
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642246
[TBL] [Abstract][Full Text] [Related]
19. Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells.
Zhong Z; Zhang H; Nan K; Zhong J; Wu Q; Lu L; Yue Y; Zhang Z; Guo M; Wang Z; Xia J; Xing Y; Fu Y; Yu B; Zhou W; Sun X; Shen Y; Chen W; Zhang J; Zhang J; Ma D; Chu Y; Liu R; Miao C
Cancer Res; 2023 Nov; 83(21):3529-3543. PubMed ID: 37602826
[TBL] [Abstract][Full Text] [Related]
20. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
